Heat Biologics (HTBX) : 2 analysts are covering Heat Biologics (HTBX) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels.
Heat Biologics (HTBX) : Currently there are 2 street experts covering Heat Biologics (HTBX) stock. The most bullish and bearish price target for the stock is $8 and $3 respectively for the short term. The average price target of all the analysts comes to $5.38. The estimated standard deviation from the target is $3.71.
For the current week, the company shares have a recommendation consensus of Buy. Also, Roth Capital initiates coverage on Heat Biologics (NASDAQ:HTBX) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $2.75 per share. The rating by the firm was issued on June 20, 2016.
Heat Biologics (NASDAQ:HTBX): The stock opened at $1.3 and touched an intraday high of $1.36 on Wednesday. During the day, the stock corrected to an intraday low of $1.3, however, the bulls stepped in and pushed the price higher to close in the green at $1.33 with a gain of 2.31% for the day. The total traded volume for the day was 523,310. The stock had closed at $1.3 in the previous trading session.
Heat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patients own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.